CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07843940 · Boehringer Ingelheim · Phase 2 · live · background · “Carboplatin” · registered Sep 2026
- NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Carboplatin” · registered Aug 2026
- NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Jul 2026
- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
| Eli Lilly and Company16% of its industry studies | 2124 studies | 2124 studies | background 49 · comparator 7 |
EtoposideRecent, repeatedEvidence- NCT07881705 · Simcere Pharmaceutical Group Limited · Phase 3 · live · background · “Etoposide Injection” · registered Oct 2026
- NCT07843940 · Boehringer Ingelheim · Phase 2 · live · background · “Etoposide” · registered Sep 2026
- NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Etoposide” · registered Aug 2026
- NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
| Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed | 1720 studies | 1721 studies | background 43 · comparator 9 |
TopotecanRecent, repeatedEvidence- NCT07365241 · AbbVie · Phase 3 · live · comparator · “Topotecan” · registered Jan 2026
- NCT07189455 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Topotecan” · registered Sep 2025
- NCT07076095 · SUNHO(China)BioPharmaceutical CO., Ltd. · Phase 2 · live · background · “topotecan hydrochloride for injection” · registered Jul 2025
- NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Apr 2025
- NCT06612151 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “topotecan hydrochloride for injection” · registered Sep 2024
| GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized | 1314 studies | 1112 studies | comparator 21 · background 7 |
atezolizumabRecent, repeatedEvidence- NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
- NCT07707895 · Boehringer Ingelheim · Phase 2 · live · background · “Atezolizumab” · registered Jul 2026
- NCT07654400 · Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 2 · live · background · “Atezolizumab” · registered Jun 2026
- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT07472517 · Boehringer Ingelheim · Phase 3 · live · background · “atezolizumab” · registered Mar 2026
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 1214 studies | 1215 studies | background 14 · comparator 4 |
lurbinectedinRecent, repeatedEvidence- NCT07796100 · Zai Lab Limited · Phase 3 · live · background · “Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin” · registered Aug 2026
- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT07365241 · AbbVie · Phase 3 · live · comparator · “Lurbinectedin” · registered Jan 2026
- NCT07155174 · AbbVie · Phase 2 · live · background · “Lurbinectedin” · registered Aug 2025
- NCT06203210 · Daiichi Sankyo · Phase 3 · live · comparator · “Lurbinectedin” · registered Jan 2024
| PharmaMar74% of its industry studiesUS: JAZZ (FDA 2020)EU: Pharma Mar S.A. (EMA 2026) | 67 studies | 67 studies | background 4 · comparator 3 |
CisplatinRecent, repeatedEvidence- NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Cisplatin” · registered Aug 2026
- NCT07559929 · Hangzhou DAC Biotechnology Co., Ltd. · Phase 2 · live · background · “Cisplatin” · registered Apr 2026
- NCT06897579 · Sino Biopharmaceutical Limited · Phase 2 · comparator · “Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection” · registered Mar 2025
- NCT05566041 · EpicentRx, Inc. · Phase 3 · live · comparator · “Cisplatin/carboplatin plus etoposide” · registered Sep 2022
- NCT05224141 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Jan 2022
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 55 studies | 56 studies | comparator 3 · background 15 |
pembrolizumabRecent, repeatedEvidence- NCT07730021 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
- NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
- NCT04332653 · NeoImmuneTech · Phase 2 · background · “pembrolizumab (KEYTRUDA®)” · registered Mar 2020
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 44 studies | 55 studies | background 8 |
IrinotecanRecent, repeatedEvidence- NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Irinotecan” · registered Apr 2025
- NCT05731518 · Biocity Biopharmaceutics Co., Ltd. · Phase 2 · live · background · “Irinotecan” · registered Jan 2023
- NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Irinotecan (drug)” · registered Dec 2022
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 44 studies | 44 studies | background 3 · comparator 1 |
tislelizumabRecent, repeatedEvidence- NCT07802821 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab” · registered Aug 2026
- NCT07502300 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Tislelizumab” · registered Mar 2026
- NCT06897579 · Sino Biopharmaceutical Limited · Phase 2 · comparator · “Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection” · registered Mar 2025
- NCT06030258 · InxMed (Shanghai) Co., Ltd. · Phase 2 · live · background · “Tislelizumab” · registered Sep 2023
| BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023) | 44 studies | 33 studies | background 2 · comparator 2 |
amrubicinRecent, repeatedEvidence- NCT07365241 · AbbVie · Phase 3 · live · comparator · “Amrubicin” · registered Jan 2026
- NCT06203210 · Daiichi Sankyo · Phase 3 · live · comparator · “Amrubicin” · registered Jan 2024
- NCT05740566 · Amgen · Phase 3 · live · comparator · “Amrubicin” · registered Feb 2023
- NCT01904253 · Otsuka Holdings Co., Ltd. · Phase 2 · comparator · “Amrubicin (Japan)” · registered Jul 2013
| Bristol-Myers Squibb67% of its industry studies | 33 studies | 33 studies | comparator 4 |
durvalumabRecent, repeatedEvidence- NCT07908537 · Merck & Co., Inc · Phase 3 · live · background · “Durvalumab” · registered Oct 2026
- NCT07174583 · IDEAYA Biosciences · Phase 2 · live · background · “durvalumab” · registered Sep 2025
- NCT06780137 · Merck & Co., Inc · Phase 2 · live · background · “Durvalumab” · registered Jan 2025
- NCT06211036 · Amgen · Phase 3 · live · background · “Durvalumab” · registered Jan 2024
| AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018) | 34 studies | 34 studies | background 4 |
PaclitaxelRecent, repeatedEvidence- NCT06954246 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2025
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
- NCT04210037 · Ascentage Pharma Group International · Phase 2 · background · “Paclitaxel” · registered Dec 2019
- NCT02038647 · Takeda · Phase 2 · background · “Paclitaxel” · registered Dec 2013
- NCT00527735 · Bristol-Myers Squibb · Phase 2 · background · “Paclitaxel” · registered Sep 2007
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 22 studies | 22 studies | background 4 · comparator 1 |
enzalutamideRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 22 studies | 11 study | background 1 · comparator 1 |
Abiraterone AcetateRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 11 study | background 1 · comparator 1 |